{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:26:43Z","timestamp":1789504003681,"version":"build-2803163510"},"reference-count":120,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.heliyon.2025.e42055","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T13:04:38Z","timestamp":1737205478000},"page":"e42055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Significance of non-steroidal anti-inflammatory drugs in the prevention and treatment of cervical cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Xun","family":"Kan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianlian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reziwanguli","family":"Aiskikaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8659-6543","authenticated-orcid":false,"given":"Yinggang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.heliyon.2025.e42055_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212571","article-title":"Cervical carcinoma: oncobiology and biomarkers","volume":"22","author":"Volkova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2025.e42055_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: opportunity and challenge","volume":"471","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e42055_bib3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.canep.2013.08.010","article-title":"Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice Research Datalink","volume":"37","author":"Wilson","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42055_bib4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/01635581.2018.1446091","article-title":"Mechanisms of phytonutrient modulation of cyclooxygenase-2 (COX-2) and inflammation related to cancer","volume":"70","author":"Desai","year":"2018","journal-title":"Nutr. Cancer"},{"issue":"6460","key":"10.1016\/j.heliyon.2025.e42055_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/367215a0","article-title":"Towards a better aspirin","volume":"367","author":"Vane","year":"1994","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e42055_bib6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00404-020-05559-6","article-title":"COX-2-PGE(2)-EPs in gynecological cancers","volume":"301","author":"Ye","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e42055_bib7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.heliyon.2025.e42055_bib8","article-title":"Extracellular ATP mediates cancer cell migration and invasion through increased expression of cyclooxygenase 2","volume":"11","author":"Sharma","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib9","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.3892\/ol.2015.3580","article-title":"Anti-inflammatory drugs and uterine cervical cancer cells: antineoplastic effect of meclofenamic acid","volume":"10","author":"Soriano-Hernandez","year":"2015","journal-title":"Oncol. Lett."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e42055_bib10","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.31557\/APJCP.2022.23.11.3801","article-title":"Aspirin restores radiosensitivity in cervical cancer cells by inducing mitotic catastrophe through downregulating G2\/M effectors","volume":"23","author":"Das","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e42055_bib11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00280-021-04343-w","article-title":"Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models","volume":"88","author":"Li","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42055_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/LGT.0000000000000104","article-title":"Aspirin and acetaminophen use and the risk of cervical cancer","volume":"19","author":"Friel","year":"2015","journal-title":"J. Low. Genit. Tract Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12032-009-9221-0","article-title":"Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells","volume":"27","author":"Xiang","year":"2010","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","article-title":"Human papillomavirus and cervical cancer","volume":"40","author":"Okunade","year":"2020","journal-title":"J Obstet Gynaecol"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2025.e42055_bib16","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex. Transm. Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1055-9965.EPI-10-1108","article-title":"Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women","volume":"20","author":"Winer","year":"2011","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e42055_bib18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2174\/1389557523666230213140641","article-title":"Role of human papillomavirus in various cancers: epidemiology, screening and prevention","volume":"23","author":"Ahmed","year":"2023","journal-title":"Mini Rev. Med. Chem."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e42055_bib19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2217\/fmb.10.107","article-title":"Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies","volume":"5","author":"Graham","year":"2010","journal-title":"Future Microbiol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1128\/JVI.78.2.821-833.2004","article-title":"Functional analysis of the human papillomavirus type 16 E1=E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization","volume":"78","author":"Wang","year":"2004","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e42055_bib21","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1128\/JVI.79.7.3998-4011.2005","article-title":"Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1\/cyclin B1 complexes","volume":"79","author":"Davy","year":"2005","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.heliyon.2025.e42055_bib22","doi-asserted-by":"crossref","first-page":"10401","DOI":"10.1128\/JVI.76.20.10401-10416.2002","article-title":"Life cycle heterogeneity in animal models of human papillomavirus-associated disease","volume":"76","author":"Peh","year":"2002","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s13402-011-0069-x","article-title":"Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value","volume":"35","author":"Ganguly","year":"2012","journal-title":"Cell. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2025.e42055_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2013.05.006","article-title":"The E5 proteins","volume":"445","author":"DiMaio","year":"2013","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.heliyon.2025.e42055_bib25","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2217\/fmb.10.107","article-title":"Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies","volume":"5","author":"Graham","year":"2010","journal-title":"Future Microbiol."},{"key":"10.1016\/j.heliyon.2025.e42055_bib26","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy","volume":"10","author":"Pal","year":"2019","journal-title":"Front. Microbiol."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e42055_bib27","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s00705-006-0821-0","article-title":"Modulation of apoptosis by human papillomavirus (HPV) oncoproteins","volume":"151","author":"Garnett","year":"2006","journal-title":"Arch. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib28","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/s41598-017-05696-0","article-title":"TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells","volume":"7","author":"Shankar","year":"2017","journal-title":"Sci. Rep."},{"issue":"44","key":"10.1016\/j.heliyon.2025.e42055_bib29","doi-asserted-by":"crossref","first-page":"18780","DOI":"10.1073\/pnas.0906357106","article-title":"HPV E6 protein interacts physically and functionally with the cellular telomerase complex","volume":"106","author":"Liu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4\u20135","key":"10.1016\/j.heliyon.2025.e42055_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000477556","article-title":"The bethesda system for reporting cervical cytology: a historical perspective","volume":"61","author":"Nayar","year":"2017","journal-title":"Acta Cytol."},{"key":"10.1016\/j.heliyon.2025.e42055_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2020.10.034","article-title":"HPV post-infection microenvironment and cervical cancer","volume":"497","author":"Yuan","year":"2021","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib32","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/427557","article-title":"Development and duration of human papillomavirus lesions, after initial infection","volume":"191","author":"Winer","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2006.11.023","article-title":"Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression--clinicopathological correlation","volume":"105","author":"Hammes","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftz048","article-title":"Association of human papillomavirus infection and inflammation in cervical cancer","volume":"77","author":"Hemmat","year":"2019","journal-title":"Pathog Dis"},{"issue":"4\u20135","key":"10.1016\/j.heliyon.2025.e42055_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bpg.2011.10.016","article-title":"Pharmacology and cellular\/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer","volume":"25","author":"Schr\u00f6r","year":"2011","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2008.01.008","article-title":"Cyclooxygenase-2 in cervical neoplasia: a review","volume":"109","author":"Young","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.heliyon.2025.e42055_bib37","article-title":"The role of aspirin in the prevention of ovarian, endometrial and cervical cancers","volume":"16","author":"Joharatnam-Hogan","year":"2020","journal-title":"Womens Health (Lond)"},{"issue":"8","key":"10.1016\/j.heliyon.2025.e42055_bib38","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1158\/0008-5472.CAN-06-4273","article-title":"Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor\/coactivator exchange","volume":"67","author":"Subbaramaiah","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/carcin\/bgp066","article-title":"Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein","volume":"30","author":"Kim","year":"2009","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e42055_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007835","article-title":"Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NF\u03baB-IL-6 signalling axis","volume":"15","author":"Morgan","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.heliyon.2025.e42055_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115673","article-title":"Genistein and\/or sulfasalazine ameliorate acetic acid-induced ulcerative colitis in rats via modulating INF-\u03b3\/JAK1\/STAT1\/IRF-1, TLR-4\/NF-\u03baB\/IL-6, and JAK2\/STAT3\/COX-2 crosstalk","volume":"214","author":"Elhefnawy","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib42","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41418-020-00693-9","article-title":"E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer","volume":"28","author":"Morgan","year":"2021","journal-title":"Cell Death Differ."},{"issue":"17","key":"10.1016\/j.heliyon.2025.e42055_bib43","doi-asserted-by":"crossref","first-page":"24361","DOI":"10.18632\/oncotarget.8222","article-title":"EGFR mediates hyperlipidemia-induced renal injury via regulating inflammation and oxidative stress: the detrimental role and mechanism of EGFR activation","volume":"7","author":"Fang","year":"2016","journal-title":"Oncotarget"},{"issue":"34","key":"10.1016\/j.heliyon.2025.e42055_bib44","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41388-023-02772-w","article-title":"Exploitation of ATP-sensitive potassium ion (K(ATP)) channels by HPV promotes cervical cancer cell proliferation by contributing to MAPK\/AP-1 signalling","volume":"42","author":"Scarth","year":"2023","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib45","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3892\/etm.2021.10150","article-title":"Chrysoeriol ameliorates COX-2 expression through NF-\u03baB, AP-1 and MAPK regulation via the TLR4\/MyD88 signaling pathway in LPS-stimulated murine macrophages","volume":"22","author":"Yoon","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42055_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/jcp.24795","article-title":"Sphingosine-1-phosphate mediates COX-2 expression and PGE2\/IL-6 secretion via c-Src-dependent AP-1 activation","volume":"230","author":"Hsu","year":"2015","journal-title":"J. Cell. Physiol."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e42055_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102628","article-title":"Reactive oxygen species-dependent activation of EGFR\/Akt\/p38 mitogen-activated protein kinase and JNK1\/2\/FoxO1 and AP-1 pathways in human pulmonary alveolar epithelial cells leads to up-regulation of COX-2\/PGE(2) induced by silica nanoparticles","volume":"11","author":"Lin","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib48","first-page":"6495","article-title":"Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumors","volume":"8","author":"Liu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.heliyon.2025.e42055_bib49","article-title":"Regulation of inflammatory pathways in cancer and infectious disease of the cervix","volume":"2012","author":"Adefuye","year":"2012","journal-title":"Scientifica (Cairo)"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib50","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3892\/ijo_00000215","article-title":"Uterine cervical carcinoma: role of matrix metalloproteinases","volume":"34","author":"Libra","year":"2009","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib51","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1210\/jcem.86.5.7442","article-title":"Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine\/paracrine regulation of neoplastic cell function via EP2\/EP4 receptors","volume":"86","author":"Sales","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2025.e42055_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5315816","article-title":"New insights in the pathogenesis of HPV infection and the associated carcinogenic processes: the role of chronic inflammation and oxidative stress","volume":"2018","author":"Georgescu","year":"2018","journal-title":"J Immunol Res"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib53","doi-asserted-by":"crossref","first-page":"6868","DOI":"10.1002\/jcb.28007","article-title":"Oxidative stress in cervical cancer pathogenesis and resistance to therapy","volume":"120","author":"Ebrahimi","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/ijgc-2020-001587","article-title":"Oxidative damage and antioxidants in cervical cancer","volume":"31","author":"Preci","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"18","key":"10.1016\/j.heliyon.2025.e42055_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184393","article-title":"Targeting ROS and cPLA2\/COX2 expressions ameliorated renal damage in obese mice with endotoxemia","volume":"20","author":"Chang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010402","article-title":"COX-2 is required to mediate crosstalk of ROS-dependent activation of MAPK\/NF-\u03baB signaling with pro-inflammatory response and defense-related NO enhancement during challenge of macrophage-like cell line with Giardia duodenalis","volume":"16","author":"Zhao","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"10.1016\/j.heliyon.2025.e42055_bib57","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10654-021-00752-6","article-title":"Systemic inflammation markers and cancer incidence in the UK Biobank","volume":"36","author":"N\u00f8st","year":"2021","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.heliyon.2025.e42055_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fimmu.2019.00071","article-title":"Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib59","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/v5020708","article-title":"Oxidative stress and HPV carcinogenesis","volume":"5","author":"De Marco","year":"2013","journal-title":"Viruses"},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2025.e42055_bib60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virusres.2007.06.018","article-title":"UVB irradiation down-regulates HPV-16 RNA expression: implications for malignant progression of transformed cells","volume":"130","author":"De Marco","year":"2007","journal-title":"Virus Res."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e42055_bib61","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2011.05.020","article-title":"Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment","volume":"309","author":"Hao","year":"2011","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib63","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canlet.2015.04.030","article-title":"Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells","volume":"364","author":"Wang","year":"2015","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib64","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdu225","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population","volume":"26","author":"Cuzick","year":"2015","journal-title":"Ann. Oncol."},{"issue":"32","key":"10.1016\/j.heliyon.2025.e42055_bib66","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2013.50.9208","article-title":"Statins and reduced risk of hepatocellular carcinoma in patients with hepatitis C virus infection: further evidence is warranted","volume":"31","author":"Bonovas","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e42055_bib67","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1056\/NEJMc051738","article-title":"Statins and the risk of colorectal cancer","volume":"353","author":"Maisonneuve","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10240","key":"10.1016\/j.heliyon.2025.e42055_bib68","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib69","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1158\/1078-0432.CCR-14-2235","article-title":"Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study","volume":"21","author":"Vidal","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.heliyon.2025.e42055_bib70","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1001\/jama.2024.4840","article-title":"Aspirin vs placebo as adjuvant therapy for breast cancer: the alliance A011502 randomized trial","volume":"331","author":"Chen","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib71","first-page":"1432","article-title":"Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function","volume":"26","author":"Zong","year":"2021","journal-title":"J buon"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib72","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s10147-017-1133-y","article-title":"Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial","volume":"22","author":"Liu","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib73","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1185\/03007995.2012.678938","article-title":"Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain","volume":"28","author":"Wolff","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/bdd.1829","article-title":"A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis","volume":"34","author":"Setoguchi","year":"2013","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42055_bib75","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2796.2000.00742.x","article-title":"Infections as a major preventable cause of human cancer","volume":"248","author":"Kuper","year":"2000","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib76","article-title":"Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia","volume":"2","author":"Grabosch","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.breast.2010.07.004","article-title":"Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk","volume":"20","author":"Ashok","year":"2011","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1940-6207.CAPR-09-0120","article-title":"Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial","volume":"3","author":"Thompson","year":"2010","journal-title":"Cancer Prev. Res."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib79","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.mehy.2013.07.033","article-title":"Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial","volume":"81","author":"Forget","year":"2013","journal-title":"Med. Hypotheses"},{"issue":"7","key":"10.1016\/j.heliyon.2025.e42055_bib80","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1096\/fj.00-0529fje","article-title":"Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells","volume":"15","author":"Stark","year":"2001","journal-title":"Faseb j"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib81","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12032-009-9221-0","article-title":"Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells","volume":"27","author":"Xiang","year":"2010","journal-title":"Med. Oncol."},{"key":"10.1016\/j.heliyon.2025.e42055_bib82","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/285374","article-title":"Aspirin has antitumor effects via expression of calpain gene in cervical cancer cells","volume":"2008","author":"Lee","year":"2008","journal-title":"J Oncol"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib83","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbrc.2012.06.067","article-title":"Aspirin enhances TRAIL-induced apoptosis via regulation of ERK1\/2 activation in human cervical cancer cells","volume":"424","author":"Im","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42055_bib84","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000529302","article-title":"Low-dose aspirin has antiproliferative and apoptosis effects in HPV16 tumor cells and delays tumor development and growth in an experimental model","volume":"88","author":"Z\u00e1rate","year":"2023","journal-title":"Gynecol. Obstet. Invest."},{"key":"10.1016\/j.heliyon.2025.e42055_bib85","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3389\/fphar.2020.01233","article-title":"The role of eicosanoids in gynecological malignancies","volume":"11","author":"Smith","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2025.e42055_bib86","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2005.12.034","article-title":"Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells","volume":"245","author":"Karl","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.heliyon.2025.e42055_bib87","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1196\/annals.1299.047","article-title":"Combination of tumor necrosis factor-alpha with sulindac in human carcinoma cells in vivo","volume":"1010","author":"Yasui","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e42055_bib88","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/cncr.11210","article-title":"Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice","volume":"97","author":"Yasui","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42055_bib89","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/ijgc-00009577-200605000-00053","article-title":"COX-1 and COX-2 expression in stage I and II invasive cervical carcinoma: relationship to disease relapse and long-term survival","volume":"16","author":"Athavale","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib90","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2007.05.008","article-title":"Influences of cyclooxygenase-1 and -2 expression on the radiosensitivities of human cervical cancer cell lines","volume":"256","author":"Jeon","year":"2007","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib91","first-page":"424","article-title":"Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine\/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1","volume":"62","author":"Sales","year":"2002","journal-title":"Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2025.e42055_bib92","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11010-009-0126-1","article-title":"COX-1 is coupled with mPGES-1 and ABCC4 in human cervix cancer cells","volume":"330","author":"Radilova","year":"2009","journal-title":"Mol. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib93","doi-asserted-by":"crossref","first-page":"123","DOI":"10.15430\/JCP.2013.18.2.123","article-title":"Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia","volume":"18","author":"Kim","year":"2013","journal-title":"J Cancer Prev"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib94","first-page":"362","article-title":"Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells","volume":"58","author":"Sheng","year":"1998","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e42055_bib95","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0968-0004(97)01107-9","article-title":"Caspases and caspase inhibitors","volume":"22","author":"Villa","year":"1997","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib96","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/147323001204000106","article-title":"Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression","volume":"40","author":"Wang","year":"2012","journal-title":"J. Int. Med. Res."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib97","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.7314\/APJCP.2016.17.4.1655","article-title":"Celecoxib, a COX-2 selective inhibitor, induces cell cycle arrest at the G2\/M phase in HeLa cervical cancer cells","volume":"17","author":"Setiawati","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib98","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ygyno.2017.02.040","article-title":"A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: the potential predictive value of VEGF serum levels: an NRG Oncology\/Gynecologic Oncology Group study","volume":"145","author":"Rader","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"51","key":"10.1016\/j.heliyon.2025.e42055_bib99","doi-asserted-by":"crossref","first-page":"e8857","DOI":"10.1097\/MD.0000000000008857","article-title":"Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer","volume":"96","author":"Guo","year":"2017","journal-title":"Medicine (Baltim.)"},{"issue":"27","key":"10.1016\/j.heliyon.2025.e42055_bib100","article-title":"A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: a preliminary, three-center, clinical trial study","volume":"98","author":"Guo","year":"2019","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib101","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MCG.0b013e3181cda097","article-title":"Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer","volume":"44","author":"Lipton","year":"2010","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib102","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-015-2947-9","article-title":"Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response","volume":"77","author":"Perroud","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib103","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.2017-0474","article-title":"Phase II trial using a combination of oxaliplatin, capecitabine, and celecoxib with concurrent radiation for newly diagnosed resectable rectal","volume":"23","author":"Araujo-Mino","year":"2018","journal-title":"Cancer. Oncologist"},{"key":"10.1016\/j.heliyon.2025.e42055_bib104","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev.med.57.121304.131253","article-title":"NSAIDs and cancer prevention: targets downstream of COX-2","volume":"58","author":"Cha","year":"2007","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.3831","article-title":"Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection","volume":"21","author":"Chen","year":"2015","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.heliyon.2025.e42055_bib106","article-title":"Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization","volume":"5","author":"Kumar","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.heliyon.2025.e42055_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672508","article-title":"Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma","volume":"11","author":"Frederico","year":"2021","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e42055_bib108","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/ijc.21616","article-title":"Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer","volume":"118","author":"Hahn","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib109","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.4049\/jimmunol.177.4.2391","article-title":"Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of Ido","volume":"177","author":"Basu","year":"2006","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e42055_bib110","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s12885-019-5676-3","article-title":"PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer","volume":"19","author":"Tuyaerts","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42055_bib111","first-page":"1485","article-title":"COX2\/PTGS2 expression is predictive of response to neoadjuvant celecoxib in HER2-negative breast cancer patients","volume":"38","author":"P","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.heliyon.2025.e42055_bib112","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.phrs.2018.02.017","article-title":"Tocotrienols: the promising analogues of vitamin E for cancer therapeutics","volume":"130","author":"Sailo","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e42055_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030656","article-title":"Molecular mechanisms of action of tocotrienols in cancer: recent trends and advancements","volume":"20","author":"Aggarwal","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e42055_bib114","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.biopha.2009.09.018","article-title":"Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling","volume":"64","author":"Shirode","year":"2010","journal-title":"Biomed. Pharmacother."},{"issue":"1a","key":"10.1016\/j.heliyon.2025.e42055_bib115","first-page":"363","article-title":"Anticancer potential of curcumin: preclinical and clinical studies","volume":"23","author":"Aggarwal","year":"2003","journal-title":"Anticancer Res."},{"issue":"18","key":"10.1016\/j.heliyon.2025.e42055_bib116","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1158\/1078-0432.CCR-05-0171","article-title":"Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells","volume":"11","author":"Lev-Ari","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e42055_bib117","first-page":"1916","article-title":"Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer","volume":"25","author":"Alqahtani","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e42055_bib118","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ijc.27686","article-title":"Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis","volume":"132","author":"Huang","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.heliyon.2025.e42055_bib119","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1158\/1078-0432.CCR-04-1741","article-title":"A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable\/unresectable non-small cell lung cancer","volume":"11","author":"Liao","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.heliyon.2025.e42055_bib120","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/jnci\/djg058","article-title":"Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?","volume":"95","author":"Choy","year":"2003","journal-title":"J Natl Cancer Inst"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025004359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025004359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:37:07Z","timestamp":1775738227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844025004359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2405844025004359"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e42055","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significance of non-steroidal anti-inflammatory drugs in the prevention and treatment of cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e42055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e42055"}}